Rising Chronic Kidney Disease Prevalence Drives Growth In Related Health Complications: A Key Driver Powering Calciphylaxis Market Growth In 2025

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Calciphylaxis Market Size and Its Estimated Growth Rate?
Recent years have seen a significant expansion in the calciphylaxis market size. It is projected to surge from $3.22 billion in 2024 to $3.55 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%. This notable growth during the historical period can be credited to the increasing frequency of chronic kidney disease, heightened awareness about rare illnesses, greater governmental funding for research into such diseases, improvements in the regulatory environment, and a rise in healare spending.

The calciphylaxis market is anticipated to witness robust expansion in the foroming years and is projected to reach $5.13 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.7%. The surge during this forecasted period is due to reasons such as an increasing aged population worldwide, the introduction of new therapeutic treatments, enhanced availability of dialysis in the developing regions, more investments being made in the development of medications for rare diseases, and a higher occurrence of terminal kidney disease. Some key trends for the forecast period include progression in dialysis and renal care, breakthroughs in treating bone and mineral disorders, evolution in personalized medicine, biotechnological advancements, therapeutic improvements, and progress in healare policies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21124

How Are Emerging Segments Shaping the Calciphylaxis Market Landscape?
The calciphylaxis market covered in this report is segmented -

1) By Type: Non-Uremic Calciphylaxis, Ulcers And Wounds, Debridement Of Wounds
2) By Treatment: Drug Therapy, Hyperbaric Calciphylaxis Therapy
3) By Diagnosis: Deep Skin Biopsies, Blood Tests, Imaging
4) By End-Use: Hospital And Clinics, Homecare, Ambulatory Centers

Subsegments:
1) By Non-Uremic Calciphylaxis: Vascular Calcification, Soft Tissue Calcification, Cutaneous Manifestations
2) By Ulcers and Wounds: Skin Ulcers, Ischemic Wounds, Necrotic Ulcers, Pressure Ulcers
3) By Debridement Of Wounds: Surgical Debridement, Enzymatic Debridement, Autolytic Debridement, Mechanical Debridement, Biological Debridement

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21124&type=smp

Which Growth Factors Are Influencing Calciphylaxis Market Expansion?
The surge in cases of chronic kidney disease (CKD) is anticipated to fuel the expansion of the calciphylaxis market. CKD is a long-lasting condition, characterized by the kidney's gradual loss of their filtering capacity, leading over time to possible kidney failure. Factors such as an aging population, a rise in the incidence of diabetes and hypertension, unhealthy lifestyle choices, and the inadequate early detection and management of kidney ailments are causing an increase in CKD. Calciphylaxis is a crucial indicator of severe vascular complications within CKD, emphasizing the importance of early intervention and better mineral imbalance management to avoid tissue necrosis and related morbidity. For instance, government agency Australian Institute of Health and Welfare reported that in December 2024, the mortality rates from CKD in Australia showed a steady rise, with a 4.2% increase in 2021 and 6.2% in 2022, with the latter year seeing more growth. As such, the rise in CKD incidents is stimulating the calciphylaxis market's expansion. Likewise, the amplifying prevalence of obesity is forecasted to boost the calciphylaxis market. Obesity, a medical condition marked by an overabundance of body fat, enhances the risk of several health problems including heart disease, diabetes, and hypertension. The climbing prevalence of obesity can be attributed to sedentary lifestyles, high-calorie diets, genetic factors, and restricted access to healthy food. Obesity heightens the risk of calciphylaxis because it exacerbates calcium-phosphate imbalance and damages the endothelial, especially in those with chronic kidney disease, due to metabolic dysfunction, chronic inflammation, and vascular calcification. For example, a US government agency, the Centers for Disease Control and Prevention, stated that in September 2023, the number of states with an adult obesity rate of 35% or more had increased to 22 in 2022 from 19 states the year before. Consequently, the mounting prevalence of obesity is propelling the expansion of the calciphylaxis market.

Who Are the Dominant Players Across Different Calciphylaxis Market Segments?
Major companies operating in the calciphylaxis market are Baxter International Inc., Opko Health Inc., Hope Pharmaceuticals Ltd

What Trends Are Driving Growth in The Calciphylaxis Market?
In the calciphylaxis market, primary businesses are putting their focus on the creation of innovative therapies such as enzyme replacement therapy for improved treatment outcomes and to lessen the severity of this medical condition. Enzyme replacement therapy (ERT) is a solution where a missing or deficient enzyme in a human body is substituted. It is generally used to address unique genetic disorders wherein the body can't produce a particular enzyme needed for regular cell activity. For example, Inozyme Pharma Inc., a biopharmaceutical company from the US, published positive interim conclusions from its INZ-701 Phase 1 SEAPORT 1 trial for patients with end-stage kidney disease (ESKD) in October 2024. The interim data points out the possibility of INZ-701 for the recovery of crucial enzyme activity for preventing unusual mineralization, an important factor in serious rare diseases. This therapy is designed specifically for ABCC6 and ENPP1 deficiencies, associated with pathological calcium accumulated in blood vessels and tissues.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/calciphylaxis-global-market-report

Which Geographic Regions Are Expected to Dominate the Calciphylaxis Market in the Coming Years?
North America was the largest region in the calciphylaxis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Calciphylaxis Market?
2. What is the CAGR expected in the Calciphylaxis Market?
3. What Are the Key Innovations Transforming the Calciphylaxis Industry?
4. Which Region Is Leading the Calciphylaxis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.